kidney issues with semaglutide in patients overweight or obesity and chronic disease without diabetes: a randomized double-blind placebo-controlled clinical trial Semaglutide for Chronic Kidney Disease:

We need to see pharmaceutical corporations put people before their astronomical profits and bring their pen prices down dramatically, so that we can put an end to this global double standard in diabetes care. A Novo Nordisk spokesperson said: While we are unaware of the analysis used in the study, we have always recognised the need for continuous evaluation of innovation and affordability levers to support greater access of our products

B12 is water-soluble, so your body clears what it does not use

If a patient has a serious B12 deficiency but is resistant to B12 injections, it is important to educate the patient about the destructive effects of B12 deficiency on the brain and the ways this may worsen their symptoms

, , ,